share_log

Needham Reiterates Buy on Immuneering, Maintains $15 Price Target

Moomoo 24/7 ·  Apr 12 06:33

Needham analyst Ami Fadia reiterates Immuneering (NASDAQ:IMRX) with a Buy and maintains $15 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment